Roche moved further into obesity by licensing an RNA interference program aimed at ALK7 from Rona Therapeutics, adding to a run of late-stage metabolic deals. The collaboration centers on targeting ALK7, a genetically validated driver implicated in obesity and related metabolic indications. Rona’s ALK7-focused RNAi asset gives Roche a new mechanism class beyond weight-loss peptides, while signaling intensifying competition to broaden obesity portfolios. The deal also follows similar ALK7 activity in the field, with other companies previously positioning around the same target. For biotech, the transaction underscores how target validation (especially genetic proof) is translating into new licensing bets as obesity demand remains high and patent timelines tighten across the class.